Medicines Patent Pool Expands From HIV To Hepatitis C & TB, With 100 Projects On The Go
Executive Summary
Drugs for hepatitis C and tuberculosis are now being licensed for generic production under the aegis of the Medicines Patent Pool, which says it now has 15 generic manufacturing partners working on more than 100 projects across the hepatitis C, TB and HIV areas.
You may also be interested in...
Latest WHO Essential Medicines List: New Drugs And A New Way Of Tackling Antibiotic Resistance
New drugs for leukemia, hepatitis C, HIV and tuberculosis have made it onto the 20th edition of the World Health Organization’s Essential Medicines List, which also features a new categorization system for antibiotics in a fresh effort to curb the rise of antibacterial resistance.
DNDi Adds Affordable Ravidasvir Combo To Asian HCV Trials
DNDi is progressing its five-year initiative to improve access to affordable combination therapies for hepatitis C through new agreements for ravidasvir, which will be tested in trials in Malaysia and Thailand.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.